Skip to main content
Clinical Trials/TCTR20240429004
TCTR20240429004
Recruiting
Phase 4

Comparative outcome of triamcinolone acetonide injection between 10 mg and 20 mg in de Quervain Tenosynovitis : A randomized controlled trial

Mahavajiralongkorn Phramongkutklao Hospital Foundation0 sites122 target enrollmentApril 29, 2024

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Triamcinolone acetonide injection in de Quervain Tenosynovitis
Sponsor
Mahavajiralongkorn Phramongkutklao Hospital Foundation
Enrollment
122
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 29, 2024
End Date
May 31, 2025
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Mahavajiralongkorn Phramongkutklao Hospital Foundation

Eligibility Criteria

Inclusion Criteria

  • 1\.Patient older than 20 years of age who have diagnosed with de Quervain tenosynovitis
  • 2\.Patient who have diagnosed with de Quervain tenosynovitis who have not previously been treated with steroid injections

Exclusion Criteria

  • 1\. Patients who had underlying inflammatory joint diseases such as rheumatoid arthritis, gouty arthritis or autoimmune disease
  • 2\. 1st CMC joint arthritis and STT joint arthritis
  • 3\. Injury to the involved wrist
  • 4\. Who had history of wrist fracture
  • 5\. Previous surgery at wrist
  • 6\. Abnormal sensation of hand
  • 7\. History of an allergy to triamcinolone acetonide or lidocaine
  • 8\.Patients who do not have a communication device that can use face\-to\-face calling and cannot follow up on treatment at outpatient department orthopedic division Phramongkutklao Hospital

Outcomes

Primary Outcomes

Not specified

Similar Trials